Edition:
United Kingdom

Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

6.60EUR
4:35pm BST
Change (% chg)

€-0.21 (-3.08%)
Prev Close
€6.81
Open
€6.72
Day's High
€6.76
Day's Low
€6.50
Volume
95,497
Avg. Vol
125,810
52-wk High
€9.18
52-wk Low
€4.92

Summary

Name Age Since Current Position

Pierre Legault

57 2016 Chairman of the Board

Thomas Kuhn

Chief Executive Officer, Director

Anne Renevot

2017 Chief Financial Officer

Noah Beerman

52 Executive Vice President - Business Development, US Operations

Christophe Abert-Engels

Executive Vice President - Clinical Development & Medical Affairs

Jonae Barnes

2016 Senior Vice President, Investor Relations and Public Relations

Sophie Bozec

Senior Vice President Pharmacology

Takashi Kaneko

2018 Senior Vice President Medical, President of Poxel Japan K.K

Sebastien Bolze

Scientific Director - Non Clinical Development

Pascale Fouqueray

Medical Director - Early Development & Translational Medicine

Thierry Hercend

2016 Director

Mohammed Baluch

Independent Director

Pascale Boissel

2015 Independent Director

Janice Bourque

2016 Independent Director

Richard Kender

63 2015 Independent Director

Kumi Sato

2017 Independent Director

Biographies

Name Description

Pierre Legault

Mr. Pierre Legault has served as Chairman of the Board of Poxel S.A. since April 18, 2016. He is Member of company's Audit, Remuneration, Business Development, Scientific as well as Strategic and Pricing Committees. He served as Director of the Company between February 1, 2016 and April 18, 2016. He joined Poxel with over 35 years of experience working in the pharmaceutical and biotechnology industry. In 2012, he became Executive Chairman and later became President and CEO of NephroGenex, a North Carolina-based biotechnology company focused on diabetic nephropathy and acute kidney injury. He was responsible for the company's successful IPO to the Nasdaq in 2014 as well as the initiation of a Phase 3 development program. From 2010 to 2012, he was President and CEO of Prosidion Ltd, which specialized in the treatment of diabetes and obesity. In 2009/2010, he was Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. From 2006 to 2007, Pierre was President of Eckerd Pharmacies. Between 1989 and 2005 he held various roles at legacy companies of Sanofi-Aventis, leading up to the position as Worldwide President Dermatology/Dermick which he held from 2003 to 2005. Pierre studied International Finance, Business & Commerce and earned a Masters of Business Administration degree in Marketing from McGill University in Montreal, Canada. He holds also a Bachelor of Business Administration degree from Hautes Etudes Commerciales.

Thomas Kuhn

Mr. Thomas Kuhn is Chief Executive Officer, and a Director of Poxel SA. He joined Merck Serono in 2000, where he held various positions in clinical development mainly for diabetes products. Between 2004 and 2007, he directed global R&D projects, with two products being in phase 2clinicaltrials, and Life Cycle Management projects, specifically for Glucophage, a diabetes treatment. With the integration of Serono in 2007, he was involved in refining the Merck Serono strategy, which led to the divestment of diabetes as an integrated therapeutic area. He was involved in the establishment of Poxel SA. Mr. Kuhn received his pharmacy degree from University of Lyon I(France) and his MBA from Ashridge University.

Anne Renevot

Ms. Anne Renevot has been Chief Financial Officer of the Poxel SA since April 25, 2017. Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS' successful IPO on Euronext Paris, which raised €39M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company's acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries. Anne Renevot received a bachelor's degree in finance from Audencia Business School in Nantes, France and a master's degree in corporate finance from Ohio State University, Columbus, Ohio.

Noah Beerman

Mr. Noah Beerman is Executive Vice President - Business Development, US Operations at Poxel SA. He joined Poxel in 2015 and has over 30 years’ experience in the biopharmaceutical industry, including building and financing public companies, strategic planning and management, negotiating global/regional partnerships, and completing M&A transactions. He began his career serving in a number of scientific and business roles at Repligen, Sandoz, Curis, and Technology Management & Funding. Mr. Beerman then joined Indevus Pharmaceuticals in 1997 and worked there through the sale to Endo Pharmaceuticals in 2009. At Indevus he was responsible for multiple licensing, co-promotion and M&A agreements, establishing an industry-leading profile in corporate development as Chief Business Officer. Subsequently, he was President, CEO and Director of RXI Pharmaceuticals from 2009 through 2011, and Executive Vice President and Chief Operating Officer at Coronado Biosciences (now Fortress Biotech) from 2011 through 2013. Prior to joining Poxel, Mr. Beerman served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics. Mr. Beerman holds an MBA from Northeastern University's High Technology Program and a Bachelor of Science in Molecular Genetics from the University of Rochester.

Christophe Abert-Engels

Dr. Christophe Abert-Engels is Executive Vice President - Clinical Development & Medical Affairs at Poxel SA. He has more than 25 years of experience in life sciences, academia and industry. Dr. Arbet-Engels’ leadership at several large pharmaceutical companies encompasses clinical development and registration, launch and lifecycle management for several innovative drugs for the treatment of diabetes, metabolism and cardiovascular diseases, including Lantus® (insulin glargine) and Jardiance® (empagliflozin). Most recently, he was Vice President, Worldwide Medical, Collaborative Medical Sciences at Biogen, driving strategy and execution of Phase 3b/4 life cycle management activities. Prior to Biogen, Dr. Arbet-Engels worked in senior leadership positions in clinical development and medical affairs at pharmaceutical and biotech companies, including Boehringer Ingelheim, Roche, Merck, Aventis (now Sanofi) and Ligand Pharmaceuticals. In addition, Dr. Arbet-Engels served as a Medical Advisor to MedNest, provided expertise to the Gerson Lehrman Group, and worked as French Foreign Trade Advisor for the French Government to advise and support French or other startup companies develop their business in the U.S. Dr. Arbet-Engels has a medical degree from University of Paris Sud, a PhD in endocrinology/diabetes and metabolism from Paris Descartes University and a master’s degree in business administration from Rutgers University.

Jonae Barnes

Ms. Jonae R. Barnes has been Senior Vice President, Investor Relations and Public Relations of POXEL S.A. since March 14, 2016. She has 20 years of experience in the pharmaceutical and biotechnology industry. She began her career at Sepracor (now Sunovion Pharmaceuticals; acquired by Dainippon Sumitomo Pharma Co.), a specialty pharmaceutical company, where she held a series of progressively responsible management and executive roles over a 14-year period and most recently served as Senior Vice President, Investor Relations, Corporate Communications and Internal Communications. Ms. Barnes has also served in senior leadership roles at Agenus, an immuno-oncology company and Vision Medicines, an ophthalmology-focused company. In addition to her corporate appointments, she has advised privately held and publicly traded biotech companies through her investor relations consulting practice in the therapeutic areas of respiratory disorders, infectious diseases, IBS, diabetes and oncology. She holds a Bachelors degree in Political Science from Suffolk University and Masters degrees in Financial Economics and Multinational Commerce from Boston University.

Sophie Bozec

Dr. Sophie Bozec is Senior Vice President Pharmacology (Diabetes) at Poxel SA. She graduated from Paris VII with a Doctorate degree in Biology. She has 16 years of experience in the field. Sophie Bozec joined Merck KGaA in 1998 where she managed a drug discovery team in a pharmacology department. Dr. Bozec has acquired a strong experience for managing research projects from target identification to preclinical development candidates. She has developed her knowledge in models (in vivo and in vitro) used in research programs for identifying preclinical development candidates in the diabetes field. She acquired a solid expertise in metabolic diseases particularly in the diabetes field. This experience in pharmacology led Dr. Bozec to support a clinical development compound for all preclinical pharmacology aspects.

Takashi Kaneko

Dr. Takashi Kaneko M.D., Ph.D., has been Senior Vice President Medical and President of Poxel Japan K.K at Poxel SA since September 1, 2018. He has 33 years of experience including pharmaceutical industry experience with a focus on medical affairs and clinical development ranging from product evaluation, development and post-commercial launch, and clinical practice and medical research experience. Dr. Kaneko joined Poxel from Janssen Pharmaceutical K.K., where he was Head of Medical Affairs. Prior to Janssen Pharmaceutical K.K., he was the Department Head of the Medical Excellence Department in the Medical Division at Novartis K.K. Dr. Kaneko also held several senior-level positions at Santen, which included the areas of Compliance, Global Clinical Development and Medical Affairs, Head of Global Research and Development as well as other research and development-related positions. In addition, he was a Vice President, Medical Director at Sanofi-Aventis K.K., and served in clinical development roles at Bristol-Myers K.K., BMS, Japan. Dr. Kaneko holds an MD and PhD degree from the University of Tokyo.

Sebastien Bolze

Dr. Sebastien Bolze is Scientific Director of Poxel SA. He has broad experience in drug development from discovery screening to first-in-man clinical trials. Dr. Bolze was global head of the preclinical candidate selection unit at Solvay Pharmaceuticals, a multidisciplinary unit providing support to research projects from optimization of validated hits to delivery of candidates for preclinical development. From 2003 to 2006, he was executive head of the ADME department at Fournier Pharma. He acquired strong organizational and managerial experience in research projects within a multidisciplinary and global environment. Dr. Bolze has also co-authored numerous research publications and posters. Dr. Bolze is a Pharmacist and holds a PhD in Pharmacokinetics and Drug Metabolism from the University of Lyon I (France).

Pascale Fouqueray

Dr. Pascale Fouqueray is Medical Director - Early Development & Translational Medicine at Poxel SA. She is a Doctor of Medicine (Angers-France), Endocrinologist (Paris-France) and Doctor of Sciences (Paris-France). She has 14 years of experience in the pharmaceutical industry (Merck Serono). She is head of exploratory clinical development of molecules in diabetes, obesity and gout at Merck Serono. Dr. Fouqueray graduated from medical school at the University of Angers (France) and then specialized in Endocrinology and Metabolism at the University of Paris V. She holds a PhD from the University of Paris XI.

Thierry Hercend

Dr. Thierry Hercend has served as Director of Poxel S.A. since April 18, 2016. He is Chairman of Scientific Committee. He served as Chairman of the Board of the Company until April 18, 2016. He has over 30 years of both academic and pharmaceutical experience in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Hercend has been Venture Partner at Andera Partners. From 2002 until 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe, at Vertex Pharmaceuticals. Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and was in various executive R & D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Immunology unit of the Gustave Roussy Cancer Institute, Villejuif, France, Director of the Inserm unit U333 dedicated to tumor Immunology and a Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, auto-immune diseases and transplantation. He holds a Doctorate in Philosophy degree from Universite de Paris.

Mohammed Baluch

Mr. Mohammed Khoso Baluch is Independent Board Member of Poxel SA. He is Chairman of Remuneration Committee, Member of Business Development Committee and Member of Scientific Committee. Currently he is also Chief Executive Officer and Board Member of CorMedix. He was Senior Vice President and President of Europe at UCB. Prior to joining UCB, Mr. Baluch worked for Eli Lilly & Co. for 24 years in various positions across Europe, the Middle East and the United States within the Management Committee, as head of business development, market access or product leadership. Mr. Baluch was also named vice president of American unity "Diabetes and Family Health" within the position he held at Lilly. He was also a member of the Council in the Indiana Division of the American Foundation. He holds Bachelor of Science from City University London and MBA from Cranfield University.

Pascale Boissel

Ms. Pascale Boissel has been Independent Director of Poxel SA since March 5, 2015. She is Chairman of company's Audit Committee and Member of Governance and Nominating Committee. She is a consultant in finance and restructuring operations, a field in which she has 25 years of experience. She is the part-time CFO of Novadiscovery, a biotech company which develops models and simulations in order to avoid the risks in developing new drugs. Before that, she was previously the Deputy-Chief Executive Officer and Head of Finance and Administration of the BIOASTER institute, a French not-for-profit organization that develops collaborative research programs in the field of infectious diseases and microbiology. In 2009, Madame Boissel joined biotech company Ipsogen in the United States and was responsible for financing activities. She played a major role in the transaction which led to completion of the acquisition of Ipsogen in 2011. Before joining Ipsogen, she worked for listed French companies, as Deputy Chief Financial Officer, in the sector of transactions and commercial control. Pascale Boissel began her career in audit and corporate finance at PricewaterhouseCoopers. She has significant experience in international accounting practices. She holds MBA from HEC and is Certified Accountant.

Janice Bourque

Ms. Janice Bourque has been Director of the Poxel SA since January 29, 2016. She is Member of the Audit Committee and Chairwoman of the Governance and Nominating Committee. She serves as Managing Director of Hercules Capital and Board Member at The Village Bank and Forsyth Institute, among others. She has served at Hercules Capital since 2010. During this time she helped early and expansion stage biotechnology companies to secure financings with investments ranging from $10 million to $60 million per company. Prior to this, she was a consultant at Commons Capital where she advised and provided strategic corporate investor fundraising. From 2005 to 2009 she was the Senior Vice President and Group Head-Life Sciences at Comerica Bank in Dallas, Texas. Janice was also President and CEO of the Massachusetts Biotechnology Council, the oldest biotechnology trade association in the world, where she was instrumental in its growth since 1992. Janice graduated from the University of New Hampshire with an MBA in Finance and Accounting.

Richard Kender

Mr. Richard Kender has served as a member of the board of directors of Poxel SA since 2015. He is Member of the Audit Committee and the Remuneration Committee, as well as Chairman of Business Development Committee and Member of the Strategic and Pricing Committee. Mr. Kender joined Merck & Co., Inc. in 1978, and served as Merck’s Vice President of Corporate Development from 1996 to 2000. In 2000, he was promoted to Senior Vice President and his responsibilities were expanded to include Corporate Licensing and Worldwide Business Development, where he managed Merck’s Mergers and Acquisitions, Licensing, Financial Evaluation and Analysis and Global Competitive Intelligence departments. Mr. Kender retired from Merck in September 2013. Mr. Kender currently serves on the board of directors and audit committee of Seres Therapeutics and on the board of directors of Abide Therapeutics. He holds a BS in Accounting from Villanova University and an MBA from Fairleigh Dickinson University.

Kumi Sato

Ms. Kumi Sato has served as Independent Director of the Company since June 30, 2017. She is Member of company's Business Development Committee. For over 30 years, Kumi Sato has served as President and CEO of Cosmo Public Relations Corporation, an award-winning strategic communications and public affairs firm based in Tokyo, Japan, with a specialized healthcare division, COSMO Healthcare. Since its founding, COSMO has consulted for over 500 companies in healthcare, food and food sciences, and the service industry. Before taking over as CEO in 1987, she founded COSMO International, which advised Japanese companies on US market entry strategies. During her time at COSMO, she has been instrumental in directing the company to broaden its international focus and has held a series of noteworthy advisor positions, such as President and Founder of Women Japan.com and Outside Director for Rokko & Associates Inc. In 2010, she founded BioCube, a think-tank to discuss Japan's healthcare system and biotech-related topics. She currently serves as an advisor to the Global Health Innovative Technology Fund in Tokyo, a lecturer at the Graduate School of Business Breakthrough University and is Chairman Emeritus of the American Chamber of Commerce in Japan. In addition, she is co-chairman of the Global Council for the Asia Society, based in New York. Ms. Sato has also authored two business textbooks on communication strategies and corporate social responsibility. Ms. Sato started her career at McKinsey & Co., New York and holds a B.A. in East Asian Studies from Wellesley College, MA.